Document
 
 




As filed with the Securities and Exchange Commission on May 25, 2018
Registration No. 333-            
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
 
Washington, D.C. 20549
 
 
 
 
 
FORM S‑8
 
 
REGISTRATION STATEMENT
 
 
Under
The Securities Act of 1933
 
 
 
 
 
VITAL THERAPIES, INC.
 
 
(Exact name of Registrant as specified in its charter)
 
 
 
 
 
Delaware
 
56-2358443
 
 
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification Number)
 
 
 
 
 
15010 Avenue of Science, Suite 200
San Diego, California 92128
 
 
(Address of principal executive offices)(Zip code)
 
 
 
 
 
Vital Therapies, Inc. 2014 Equity Incentive Plan
 
 
(Full title of the plan)
 
 
 
 
 
 
Russell J. Cox
Chief Executive Officer
15010 Avenue of Science, Suite 200
San Diego, California 92128
(858) 673-6840
 
 
 
(Name, address and telephone number, including area code, of agent for service)
 
 
 
Copies to:
 
 
 
 
Martin J. Waters
Wilson Sonsini Goodrich & Rosati,
Professional Corporation
12235 El Camino Real, Suite 200
San Diego, California 92130
(858) 350-2300
 
 
 
 
 
 
 
 
 
 
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
¨
Accelerated filer
ý
 
 
 
 
Non-accelerated filer
¨  (Do not check if a smaller reporting company)
Smaller reporting company
¨
 
 
 
 
 
 
Emerging growth company
ý
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
ý




 
 
 
Title of Securities
to be Registered
Amount
to be
Registered
(1)

Proposed
Maximum
Offering Price
Per Share
(2)
Proposed
Maximum
Aggregate
Offering Price
Amount of
Registration Fee

Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the Vital Therapies, Inc. 2014 Equity Incentive Plan
1,200,000 (2)
$6.19 (3)
$7,428,000
$924.79
 
 
 
 
 
 
 
 
 
(1
)
Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of the Registrant’s common stock that become issuable under the Vital Therapies, Inc. 2014 Equity Incentive Plan (“2014 Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant’s outstanding shares of common stock.
(2
)
Represents shares of the Registrant’s common stock that were automatically added to the shares authorized for issuance under the 2014 Plan on April 16, 2018 pursuant to an “evergreen” provision contained in the 2014 Plan. Pursuant to such provision, effective on the date of the effectiveness of the registration statement on Form S-1 relating to the Registrant’s initial public offering (or April 16, 2014), and on each anniversary date thereafter, the number of shares available for issuance under the 2014 Plan is automatically increased in an amount equal to the least of: (i) 1,200,000 shares of the Registrant’s common stock; (ii) 3% of the outstanding shares of the Registrant’s common stock on the second-to-last day prior to each anniversary date; (iii) an amount as the Registrant’s board of directors may determine.
(3
)
Estimated in accordance with paragraphs (c) and (h) of Rule 457 solely for the purpose of calculating the total registration fee. Computation based on the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Global Market on May 21, 2018.
 
 
 
 
 
 
 
 
 






PART I
INCORPORATION BY REFERENCE OF CONTENTS OF
REGISTRATION STATEMENT ON FORM S-8 NOS. 333-196571, 333-204644, 333-211359 and 333-218298
This Registration Statement is being filed for the purpose of increasing the number of securities of the same class for which a Registration Statement on Form S-8 relating to the same benefit plan is effective. The Registrant previously registered shares of its common stock for issuance under the 2014 Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on June 6, 2014 (File No. 333-196571), on June 2, 2015 (File No. 333-204644), on May 13, 2016 (File No. 333-211359) and on May 26, 2017 (File No. 333-218298). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.







PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
Vital Therapies, Inc. (the “Registrant”) hereby incorporates by reference in this Registration Statement the following documents and information previously filed with the Commission:
(1)    The Registrant’s annual report on Form 10-K for the fiscal year ended December 31, 2017 (File No. 001-36201), filed with the Commission on March 13, 2018, as amended on March 14, 2018;
(2)    The Registrant’s quarterly report on Form 10-Q for the quarter ended March 31, 2018, filed on May 8, 2018;
(3)    All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of the fiscal quarter covered by the Registrant’s quarterly report referred to in (2) above; and
(4)    The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-36201) filed with the Commission on November 15, 2013, pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.
All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement.
Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.





Item 8. Exhibits

Exhibit
Number
 
Description
4.1(1)
 
Specimen Common Stock Certificate of the Registrant.
4.2(2)
 
Vital Therapies, Inc. 2014 Equity Incentive Plan and related form agreements.
4.3(3)
 
Amended Global Stock Option Agreement under 2014 Equity Incentive Plan.
5.1
 
23.1
 
23.2
 
Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto).
24.1
 
Power of Attorney (contained on signature page hereto).
 
 
 
(1)
Incorporated by reference to Exhibit 4.1 filed with Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (Registration No. 333-191711), filed with the Commission on November 6, 2013.
(2)
Incorporated by reference to Exhibit 10.11 filed with Amendment No. 4 to the Registrant’s Registration Statement on Form S-1 (Registration No. 333-191711), filed with the Commission on March 11, 2014.
(3)
Incorporated by reference to Exhibit 10.13 filed with the Registrant’s Annual Report on Form 10-K (File No. 001-36201), filed with the Commission on March 13, 2018, as amended on March 14, 2018.






SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on May 25, 2018.
VITAL THERAPIES, INC.
By:    /s/ Russell J. Cox    
Russell J. Cox
Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Russell J. Cox and Michael V. Swanson, and each of them, as his or her true and lawful attorney in fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including post effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney in fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney in fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.






Signature
 
Title
 
Date
/s/ Russell J. Cox
 
Director and Chief Executive Officer
 
May 25, 2018
Russell J. Cox
 
(Principal Executive Officer)
 
 
 
 
 
 
 
/s/ Michael V. Swanson
 
Chief Financial Officer (Principal Financial
 
May 25, 2018
Michael V. Swanson
 
Officer and Principal Accounting Officer)
 
 
 
 
 
 
 
/s/ Faheem Hasnain
 
Chairman
 
May 25, 2018
Faheem Hasnain
 
 
 
 
 
 
 
 
 
/s/ Jean-Jacques Bienaimé
 
Director
 
May 25, 2018
Jean-Jacques Bienaimé
 
 
 
 
 
 
 
 
 
/s/ Cheryl L. Cohen
 
Director
 
May 25, 2018
Cheryl L. Cohen
 
 
 
 
 
 
 
 
 
/s/ Douglas E. Godshall
 
Director
 
May 25, 2018
Douglas E. Godshall
 
 
 
 
 
 
 
 
 
/s/ Errol R. Halperin
 
Director
 
May 25, 2018
Errol R. Halperin
 
 
 
 
 
 
 
 
 
/s/ J. Michael Millis, M.D.
 
Director
 
May 25, 2018
J. Michael Millis, M.D.
 
 
 
 
 
 
 
 
 
/s/ Muneer A. Satter
 
Director
 
May 25, 2018
Muneer A. Satter
 
 
 
 
 
 
 
 
 
/s/ Lowell E. Sears
 
Director
 
May 25, 2018
Lowell E. Sears
 
 
 
 
 
 
 
 
 





INDEX TO EXHIBITS
Exhibit
Number
 
Description
4.1(1)
 
Specimen Common Stock Certificate of the Registrant.
4.2(2)
 
Vital Therapies, Inc. 2014 Equity Incentive Plan and related form agreements.
4.3(3)
 
Amended Global Stock Option Agreement under 2014 Equity Incentive Plan.
5.1
 
23.1
 
23.2
 
Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto).
24.1
 
Power of Attorney (contained on signature page hereto).

(1)
Incorporated by reference to Exhibit 4.1 filed with Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 (Registration No. 333-191711), filed with the Commission on November 6, 2013.
(2)
Incorporated by reference to Exhibit 10.11 filed with Amendment No. 4 to the Registrant’s Registration Statement on Form S-1 (Registration No. 333-191711), filed with the Commission on March 11, 2014.
(3)
Incorporated by reference to Exhibit 10.13 filed with the Registrant’s Annual Report on Form 10-K (File No. 001-36201), filed with the Commission on March 13, 2018, as amended on March 14, 2018.